Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline for Disseminated and Meningeal Coccidioidomycosis
NCT02908334Phase 2Withdrawn
- Sponsor
- University of California, San Francisco
- Start
- Nov 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of sertraline in coccidioidomycosis, sponsored by University of California, San Francisco. Primary endpoint: Adverse Reactions at 2 years. Planned start Nov 2016; status: withdrawn.
02
Drugs
sertraline
03
Conditions
coccidioidomycosis
Beyond the preview
Go deeper on NCT02908334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908334.